Biotech Absci sees shares soar in IPO debut 27-Jul-2021 By Jane Byrne Absci Corp, a Vancouver, Washington headquartered synthetic biology company developing technologies to accelerate drug discovery, has gone public.
Coming of Phage: Clinical trial underscores safety of technology battling E. coli triggered UTIs 25-Feb-2021 By Jane Byrne Locus Biosciences says the results of its early stage clinical trial for CRISPR-enhanced bacteriophage therapy shows its precision medicine asset is safe and well tolerated.